Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.79, $4.04 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $6.29 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.